Abbott schedules a USD 0.63 dividend payable November 16, 2026 for Abbott Laboratories stock

Published on 10/26/2026 at 16:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Market value hit USD 181.3 billion on October 26, 2026. Abbott Laboratories stock costs EUR 93.80 on October 26, 2026, up 2.09 percent versus Xetra close.

Dividend payment and market figures

Abbott schedules a USD 0.63 dividend payable November 16, 2026.
Abbott Laboratories had a USD 181.3 billion market capitalization on October 26, 2026.
Abbott Laboratories stock costs EUR 93.80 at Lang & Schwarz on October 26, 2026 at 3:45 p.m. CET, 2.09 percent above the Xetra close of October 23, 2026 at EUR 91.88.
Abbott reaffirmed adjusted earnings-per-share guidance of USD 5.50 to USD 5.55 for fiscal year 2026.

Abbott Laboratories, US0028241000, Illustration mit AI erstellt.

Abbott Laboratories scheduled a USD 0.63 dividend payable on November 16, 2026, to shareholders of record at the close of business on October 15, according to Abbott Laboratories. Abbott Laboratories stock was trading at EUR 93.80 at Lang & Schwarz on October 26, 2026 at 3:45 p.m. CET, up 2.09 percent versus the Xetra close of October 23, 2026 at EUR 91.88.

Dividend date adds a cash milestone

The November 16 payment is the next dated shareholder event identified in the company release. The record date was October 15, 2026, so the payment schedule follows the completed eligibility date rather than introducing a new earnings catalyst.

Abbott's latest release also projected fourth-quarter 2026 adjusted diluted earnings per share of USD 1.62 to USD 1.67. For fiscal year 2026, the company reaffirmed adjusted diluted earnings per share guidance of USD 5.50 to USD 5.55, while the third-quarter adjusted figure was USD 1.42, according to Abbott Laboratories.

Stock position and valuation

The latest U.S. quotation put Abbott Laboratories at USD 104.77 on the NYSE on October 26, 2026 at 11:00 a.m. ET. Its USD 181.3 billion market capitalization and trailing P/E ratio of 38.82 place the valuation above the company's recent earnings multiple implied by the third-quarter GAAP diluted earnings per share of USD 0.53.

The 52-week NYSE range was USD 81.97 to USD 132.03 on October 26, 2026. The current U.S. quotation stood 20.65 percent below the 52-week high and 27.81 percent above the 52-week low. Abbott's 1,436,195-share volume at that time provided a dated measure of early-session activity.

What does the dividend mean for valuation?

The dividend supplies a concrete cash-flow date, while the valuation remains tied to earnings delivery. The company operates across medical devices, diagnostics, nutrition and established pharmaceutical products, giving the payment its context within a diversified healthcare business rather than a single-product story.

Abbott Laboratories has 115,000 full-time employees and is headquartered in North Chicago, Illinois. Its medical-device operations include cardiovascular and diabetes-care products, while diagnostics and nutrition provide additional operating divisions.

Price stays above the Xetra close

The euro quotation was EUR 1.92 above the Xetra close of October 23, 2026, equivalent to a 2.09 percent increase. The next dated shareholder cash event is the USD 0.63 payment on November 16, 2026.

The further course of trading is shown by the continuously updated real-time quote of Abbott Laboratories stock.